We perform further analysis of gene expression data from a panel of 9 cancer cell lines from diverse tumor types (Supplementary Table S3 : HA1E, HCC515, A375, A549, HEPG2, HT29, MCF7 PC3, and VCAP) treated with 3,096 therapeutic inhibitors in the Library of Integrated Network-Based Cellular Signatures (LINCS) Program to determine whether the AP-2alpha gene expression signature is also associated with therapeutic response in other cancer types and to other targeted agents. This evidence concerns the gene SERPINF2 and cancer.